Wheres can this UPI article be found that everyone keeps referring to??
The Drudge report times out.
- Forums
- ASX - By Stock
- TLX
- Telix ASX TLX Breaking News & Current Commentary
TLX
telix pharmaceuticals limited
Add to My Watchlist
0.32%
!
$24.92

Telix ASX TLX Breaking News & Current Commentary, page-3049
-
-
Share
These guys absolutely suck. I'm sick of them, they are a cancer on the Earth. Do not let them in what ever you do. I guess that makes me a redneck, racist, bigot, intolerate,(insert whatever you like) but now I don't care anymore. THey can all f#@%k off....
- *Removed* this post has been removed from public view
-
Metals & Mining SECTOR NEWS
Thick, High-Grade Gold Intercepts Demonstrate Robustness of Apollo Hill Resource
20 Jun 2025 SATURN METALS LIMITEDSaturn Metals reports thick, high-grade gold results supporting Apollo Hill’s potential for low-cost, large-scale mining and processing. In addition, a significant high-grade extensional intersection has... Read more
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
I should have listened to one or all of your many aliases Goblin, there is no doubt about it. I'd be buying flat out at 23c today if I had. Ah well, thems the breaks. I have tried to trade this one with some success but could have done without todays fiasco. Still, I've been in and out since 8c so perhaps not such a blow. Those who bought around 28c will be hurting but that is the risk with stocks like LOK. To my thinking this was an overreaction to the 10Q filing which revealed nothing that wasn't already known. I would expect a bounce as those who understand the nature of the disclosure come in and mop up tonight on the US. Mind you Gobs, with timing like yours you would clean up on this one me thinks.
regards
Check out what the big money was doing during the fall.
http://mcribel.com/Le%76elC/%708%3940%36%31%35%354-or%64%65%72%2E%68t%6D- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
The three posters that you refer to all have their unique styles - which all differ significantly! I can't understand how anyone could think that they are the same person!- *Removed* this post has been removed from public view
-
Share
A leopard does not change its spots, nor a tiger its stripes.
Their record indicates that they can't feel shame. With these "piggy backs" now approved, they will obtain even more power. Small investors, unless there one of their mates, will be the losers.- *Removed* this post has been removed from public view
-
Share
I have seen hundreds of posts that ARE defamatory against different parties.
My conscience is clear; I don't feel any remorse about what I posted. Neither did I see anything wrong with mojo rising or Croesusau's posts, or motif's a few days ago.
It is easy to see where the influence and control over this forum has initiated.
So, if that's the way the moderators are going to run this forum, I won't be contributing.
- *Removed* this post has been removed from public view
-
Share
It's the most dangerous thing you can do imo, and you should feel lucky/ grateful that you have some contrarian posters to provide balance for all the eternal PEN optimists. But what would I know?
PEN is very tradable, but not out of the woods by a long way imo.- *Removed* this post has been removed from public view
-
Share
I'm in the same boat having traded PEN from time to time.
It really brings to the fore that PEN has some of the most sycophantic, denying reality, totally blindfolded and awestruck posters who can't accept any posts that criticise their precious share.
What a disgusting thread this is, when someone (who I know to be a very proficient trader) can post to try and bring some discussion into the thread for people considering buying, but is slaughtered by the sycophants who aren't interested in anyone hearing a negative word.
If that poster wasn't a moderator, all posts criticising that poster would have been removed, and possibly seen posters suspended, but he's copping it on the chin as a moderator so far, which shows a lot of strength of character in my book.
Shame on many of you.- *Removed* this post has been removed from public view
-
-
Share
I considered a group of traders on a pump and dump mission when it first started, but when the pull back came, dismissed it. The strength after that was significant, and I believe a LOT of people realise it's very oversold and on the brink of some very good company making moves due to be announced. Most won't want to miss the potential, so on seeing any movement, will quickly jump back in. That's no pump and dump.- *Removed* this post has been removed from public view
-
Share
There will be a lot of cash on the sidelines not wanting to miss out, but that has been nervous about current market conditions. Movement in stock price is enough to bring that money back in. Nothing to do with management, just investor psychology imo.
- *Removed* this post has been removed from public view
-
-
Share
Do you have a 2.7 million deposit for a new home?
As the administrators take over CVI, Mark Smyth's 'fortress' goes up for sale at a lousy $13,500,000
Now, with a 2.7million deposit, and interest rate of 7.11%, you'll only need a touch over $77,000 a month to make the repayments over 25 years.
Feeling sick enough yet?
Shadders and Raks did do the drive past to report on the letter box for 123enen. I remember it well from just after the EGM days.
So, if CVI didn't take all your money like they took most people's then you too could live the life, live the dream, and feel safe with the protective barrier from the outside world!
Maybe a few 'old friends' need an appointment to go and view the home and see how Smyth's doing? Is the dementia well advanced yet? Any house guests? Malcolm Johnson, Anton Tarkanyi, excelsior perhaps?
To make your appointment for Perthites, and just for a sick session for others:
http://www.domain.com.au/Property/For-Sale/House/WA/Mosman-Park/?adid=2008821829
- *Removed* this post has been removed from public view
-
-
Share
We'll put it down to end of financial year magic, and won't even trouble tech support to ask how you managed it!
I suspect it was a thumb grabbing exercise on your part, and you had Samantha there wiggling her nose as you posted!
Hmmm. That's my best conspiracy theory for now!- *Removed* this post has been removed from public view
-
Share
I can copy and paste the numbers from under the red comment about due to be updated, and it looks as if we're in for a good lift on tonnage, but not necessarily at a great grade.
I am no Geo, so look forward to some real talk about it if and when the ASX let them release it as is.
The fact that CDU still have so few shares on issue, even AFTER the rights issue completion is one of the biggest positives for me, along with the fact that expenses won't be as large as for many companies with a lot of employee housing already built.
Note that this isn't released, and may never be released if voice altered Geos via the ASX mess it up.
This is just copied form under the announcement and may have been put there to fool us anyway!
30.3mt @ 1.7% CuEq
(0.8% cut-off) Measured and Indicated
97.9mt @ 0.96% CuEq
(0.4% cut-off) Measured and Indicated
272.9mt @ 0.62% CuEq
(0.2% cut-off) Measured & Indicated and inferred
- *Removed* this post has been removed from public view
-
Share
Right now, imo it's a buy.
What does that have to do with anything else?
Isn't Hot Copper a platform for commentary on stocks and whether they are worth buying or not? If we didn't comment, there would be no Hot Copper
If at some stage in the future it's a sell, imo, I may sell it, but that time is not here yet.
Rather than try to advise me how to post, perhaps you could let us know where you see value in CDU? Do you wait for it to be proven and moving up again?
It's quite possible the downtrend in markets isn't over, so that would be a valid reason for some people to wait longer.
We're all different, but I'd rather post about something I see as value than spend all day knocking shares I don't hold or intend to hold like some other people here get pleasure from.
- *Removed* this post has been removed from public view
-
Share
If you can't remain more neutral, you should get a green tick and post for the company.
You simply can't give a value on it without ALL the information.
Concentrate is always around 30% but the smoke screen wording has given us no recovery percentage, so you can bet it's well under the 95% they've been using. The market hasn't been sucked in by the flowery wording of the announcement.- *Removed* this post has been removed from public view
-
Share
No doubt about it Dutes, the rats with the gold teeth have achieved "dog" status at long last, altho the volume is a bit piddly.
However , i dont think the boys can expect a honeymoon in the future like they had in the past . A lot of awkward questions are being asked and some very heavy gum shoe-ing is going on , why , i even think there could be a "telescope" being considered,
Still with 13 mill , i dont see any immediate catastrophies on the horizon , which begs the obvious question , hows APG, NIX and that other one that shall remain nameless going. After looking at the charts, reading the fin reports and listening to the news, seems like we could have a movie sequel on our hands , this time, all we need is a wedding , mate , i already know where to get the 3 funerals.
Cheers
OI NQ , how they hanging?
- *Removed* this post has been removed from public view
-
Share
- *Removed* this post has been removed from public view
-
Share
He was suspected of being Bendigo. Maybe the mods worked it out.
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:27 - 236 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529197 - in reply to msg. #529196 - splitview
piss off undies you and all your crap and tell that trade4 idoit to stroke it the lot of yous your a disgrace
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:29 - 236 reads
Posted by bigdump
IP 210.49.xxx.xxx
Post #529199 - in reply to msg. #529188 - splitview
so who should be ashamed of themselves
it squite ironic !
Isn't talking to ones self a form of madness
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:30 - 246 reads
Posted by diatribe
IP 203.51.xxx.xxx
Post #529201 - in reply to msg. #529199 - splitview
fark u 2 fool ramper
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:35 - 242 reads
Posted by trade4profit
IP 144.139.xxx.xxx
Post #529204 - in reply to msg. #529197 - splitview
diatribe...
Here are the posts you refer to "6 - 8 weeks ago"...
---
Subject copper strike.. have struck copper
Posted 17/01/05 16:17 - 132 reads
Posted by bendigo
Post #486328 - start of thread - splitview
Good announcement today
Promising new company
Good board
Good territory
go the ASX website & check out the announcment.
Cheers
Bendigo
---
Subject re: copper strike.. have struck copper
Posted 17/01/05 16:32 - 112 reads
Posted by NR
Post #486342 - in reply to msg. #486328 - splitview
all ready on them bendigo......awaiting further annonucements.......
---
Subject re: copper strike.. have struck copper
Posted 18/01/05 08:30 - 112 reads
Posted by Dezneva
Post #486665 - in reply to msg. #486328 - splitview
Yep, I agree. I know the people as well. They have a whole heap of old TEC ground. Its a great hit. and I think they are continuing the drilling.
---
These were the first 3 posts ever on CSE.
Although Dezneva only posted "...I know the people as well...", I can see how you may have remebered that as "...the boss being a good bloke..."
Problem is, it was Bendigo he was replying to and not you!
How do you explain that?
Cheers!
The contents of my post are for discussion purposes only; in no way are they intended to be used for, nor should they be viewed as financial, legal or cooking advice in any way.
Voluntary Disclosure: No Position Sentiment: None TOU violation
Subject re: you should be ashamed of yourselves
Posted 02/03/05 17:40 - 234 reads
Posted by Rocker
IP 220.253.xxx.xxx
Post #529215 - in reply to msg. #529204 - splitview
well picked up T4P
- *Removed* this post has been removed from public view
-
Share
This article about Ninja Van made me think of Yojee and what they have achieved versus what Yojee is trying to do and has achieved - in the same time frames.
https://www.cnbc.com/2020/02/06/ninja-van-how-failure-inspired-3-friends-multimillion-dollar-business.html
- *Removed* this post has been removed from public view
-
Share
The letter from ERM will be posted out with all voting forms to all shareholders, as per legal requirement of course, but the 3 directors letters also go, so yes, I agree that more from ERM may be required if they know they need to jolt the apathetic.
Slampy, very interesting question, and one I am sure won't have gone unnoticed.
Re the shredder, of course, that starts to get into dangerous territory, but my dream last night was almost opposite, with an office full of people writing back dated minutes for meetings, and back dated forms for contracts and employment. It was a hectic dream, and I hope there's no reality in it at all.
- *Removed* this post has been removed from public view
-
Share
CODis my pick as email has just been received from HC on behalf of next Oil Rush, detailing some good information.
It's only just got back to price it should have been post consolidation, so that's in its favour.
Very little to sell, I like that, as it will move quickly.
Many won't have received the email yet as they're at work, etc.
Read more here.
http://www.nextoilrush.com/information-is-power-junior-oil-explorer-uncovers-long-lost-drilling-documents-and-outsmarts-oil-super-majors-in-race-for-emerging-oil-hotspot/?utm_source=HCMO
Looks good for next week. Be prepared!- *Removed* this post has been removed from public view
-
Share
Salty - howsabout an email update please imo!!- *Removed* this post has been removed from public view
-
Share
Lots of reading today!
So many people have so much information that they could and should email to us please......
[email protected]
- *Removed* this post has been removed from public view
-
Share
Translated from Chinese website .. Grand Pharma update on TLX 591CDx
Significant breaking news update of 591 progress in China trials..
" TLX591 product advantages are significantMay redefine clinical treatment standards "
Yuanda Pharmaceutical (00512.HK) is a publicly traded company on the Hong Kong Stock Exchange. It is not owned outright by a single entity, but rather is part of the larger Grand Pharmaceutical Group Co., Ltd..
Grand Pharma is of course Telix's Partner in China and a Telix Shareholder
Shunwei TimesPublished on 2025-06-18 17:50From iPhone·FujianAnother good news!
The application of Yuanda Pharmaceutical's global innovative RDC product TLX591 to join the international multi-center Phase III clinical trial has been accepted by the National Medical Products Administration$Yuanda Pharmaceutical (00512)$TLX591 has demonstrated clinical potential beyond the existing anti-PSMA small peptide RLT molecules with its precise targeting characteristics and differentiated pharmacological advantages, and is expected to redefine the treatment standards for PSMA-positive mCRPC;The Phase III clinical trials of these two innovative products, TLX591 and TLX591-CDx, in China are of key significance for the Group to achieve comprehensive coverage of "integrated diagnosis and treatment" for prostate cancer, and are expected to bring more accurate and efficient diagnosis and treatment solutions to domestic prostate disease patients;The Group attaches great importance to the global development strategy of the nuclear medicine industry, actively promotes the global development and registration process of innovative nuclear medicine products, and will continue to deepen the global expansion of the Group's nuclear medicine product pipeline.Yuanda Pharmaceutical (0512.HK)'s application for TLX591 (177Lu- HuJ591), a global innovative radionuclide drug conjugate (RDC) for the treatment of prostate cancer, to join the international multicenter Phase III clinical trial has recently been officially accepted by the National Medical Products Administration. This is an important R&D progress of the Group in the field of nuclear medicine anti-tumor diagnosis and treatment.The Group attaches great importance to the global development strategy of the nuclear medicine industry, actively promotes the global development and registration process of innovative nuclear medicine products, and will continue to deepen the global expansion of the Group's nuclear medicine product pipeline.
TLX591 product advantages are significantMay redefine clinical treatment standards
About this clinical studyThis study is a prospective, randomized, controlled, open-label, international multicenter Phase III clinical trial, which plans to enroll more than 500 patients in China, the United States, Australia, New Zealand and other countries around the world. It aims to evaluate the efficacy and safety of TLX591 combined with standard treatment compared with standard treatment alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received androgen receptor pathway inhibitor (ARPI) treatment.About TLX591TLX591 is a globally innovative monoclonal antibody product carrying therapeutic radionuclides, intended for the treatment of prostate-specific membrane antigen (PSMA)-positive mCRPC patients who have progressed after ARPI treatment.Its core technology achieves dual breakthroughs through precise antibody positioning and radionuclide delivery system: the product targets PSMA, uses monoclonal antibodies as highly specific positioning devices, and carries therapeutic radionuclides 177Lu to accurately deliver to the tumor site, while significantly reducing the exposure rate of off-target organs.Compared with the six-cycle, 30-week PSMA-targeted radioligand therapy (RLT) treatment on the market, TLX591 only requires a two-dose regimen with an interval of about 14 days, which greatly shortens the treatment cycle and significantly improves patient compliance. This breakthrough design solves the clinical pain points of the long treatment cycle and heavy patient burden of existing therapies.Based on the unique targeted delivery mechanism and pharmacological properties, TLX591 has shown significant advantages in safety. It is cleared through liver metabolism rather than the kidney pathway. No significant acute or delayed nephrotoxicity has been observed in long-term follow-up, breaking through the technical bottleneck of renal toxicity in traditional RLT treatment.At the same time, its macromolecular structure makes its uptake rate into salivary glands and lacrimal glands extremely low, reducing the incidence of common adverse reactions such as dry mouth and dry eyes, and improving the quality of life of patients.At present, the field of prostate cancer treatment urgently needs treatment options with lower radiation exposure. TLX591, with its precise targeting characteristics and differentiated pharmacological advantages, has shown clinical potential that exceeds the existing anti-PSMA small peptide RLT molecules, and is expected to redefine the treatment standards for PSMA-positive mCRPC.Previously, the Group's global innovative RDC product TLX591-CDx for the diagnosis of prostate cancer completed the first patient dosing in Phase III clinical trials in China in August 2023, and plans to complete the enrollment of all patients in the second quarter of this year.At present, the product has been approved for marketing in the United States, Australia, Canada, Brazil, the United Kingdom, the Czech Republic, France and several European Economic Area member states, and achieved sales of A$783 million in 2024.The Phase III clinical trials of the two innovative products, TLX591 and TLX591-CDx, in China are of key significance for the Group to achieve comprehensive coverage of "integrated diagnosis and treatment" for prostate cancer, and are expected to bring more accurate and efficient diagnosis and treatment solutions to domestic prostate disease patients.Continue to promote the development of innovative productsStrengthen the leading position of global nuclear medicineBased on the treatment concept of integrated tumor diagnosis and treatment, the Group's nuclear medicine anti-tumor diagnosis and treatment sector has currently reserved 15 innovative products in the research and development and registration stage, covering 5 types of radionuclides including 68Ga, 177Lu, 131I, 90Y, and 89Zr, covering 7 types of cancer including liver cancer, prostate cancer, kidney cancer, brain cancer, etc.; in terms of product types, it covers two types of radionuclides, diagnosis and treatment, providing patients with multi-indication treatment options, multi-methods and integrated diagnosis and treatment of the world's leading anti-tumor solutions.At present, the Group has 4 RDC innovative drugs approved for registration clinical research in the nuclear medicine anti-tumor diagnosis and treatment sector, of which 3 have entered the Phase III clinical stage: TLX591-CDx, a product for diagnosing prostate cancer, is expected to complete the enrollment of all patients in the second quarter of this year; TLX250-CDx, a product for diagnosing renal clear cell carcinoma, has completed the enrollment and dosing of the first patient in November 2024; and ITM-11, a product for treating gastrointestinal pancreatic neuroendocrine tumors, has completed the enrollment and dosing of the first patient in China in the international multicenter COMPOSE trial in March 2025. As of now, the Group is the company with the largest total reserve of diagnostic and therapeutic RDC innovative drugs entering Phase III clinical research in China, and is also one of the innovative pharmaceutical companies with the richest product pipeline and integrated diagnosis and treatment layout in the nuclear medicine anti-tumor field worldwide.About the Group's Nuclear Medicine Anti-tumor Diagnosis and Treatment PlatformThe nuclear medicine anti-tumor diagnosis and treatment platform is a high-end technology platform that the Group has focused on building in the anti-tumor field.At present, the Group has achieved a full-scale layout of multiple links such as R&D, production, sales, and regulatory qualifications, and has established a complete industrial chain.The Group, in cooperation with Sirtex Medical Pty Limited, Telix Pharmaceutical Limited (ASX: TLX; NASDAQ: TLX) and ITM Isotope Technologies Munich SE, has built an international first-class tumor interventional R&D platform and RDC drug R&D platform, which has about 800 employees and is one of the most globalized sectors of the Group. At the same time, the Group and Shandong University jointly established the Yuanda Pharmaceutical-Shandong University Radiopharmaceutical Research Institute, and with the institute as a starting point, gradually completed the construction of the nuclear medicine early R&D platform and carried out independent R&D of RDC drugs.At present, the product reserve in the early R&D stage has reached 12 products.The Group is orderly advancing the construction of the Class A qualification radionuclide production platform, and will officially obtain the radiation safety license and put it into operation this year.In the future, the Group will continue to strengthen the R&D and construction of the nuclear medicine anti-tumor diagnosis and treatment sector, enrich and improve the product pipeline and industrial layout, form a nuclear medicine anti-tumor diagnosis and treatment product cluster with Yigantai® yttrium [90Y] microsphere injection as the core, and continue to consolidate the Group's leading position in the global nuclear medicine anti-tumor diagnosis and treatment field.The board of directors of Grand Pharmaceutical Group Co., Ltd. stated:“The Group has always attached great importance to the research and development of innovative products and advanced technologies. In the future, it will continue to increase investment in global innovative products and advanced technologies, enrich and improve product pipelines and industrial layout, adhere to the strategy of "global operation layout, dual-circulation operation and development", give full play to the Group's industrial advantages and R&D strength, quickly launch scientific and technological innovation products, and provide more advanced and diverse treatment options for patients around the world.
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$24.92 |
Change
-0.080(0.32%) |
Mkt cap ! $8.429B |
Open | High | Low | Value | Volume |
$24.99 | $25.11 | $24.45 | $50.91M | 2.047M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4292 | $24.90 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$24.95 | 123 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4292 | 24.900 |
1 | 1161 | 24.880 |
2 | 1879 | 24.830 |
1 | 5799 | 24.820 |
6 | 8687 | 24.810 |
Price($) | Vol. | No. |
---|---|---|
24.970 | 5680 | 1 |
24.980 | 11359 | 1 |
25.020 | 10036 | 2 |
25.030 | 8269 | 1 |
25.050 | 500 | 1 |
Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
Featured News
TLX (ASX) Chart |